These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34455300)

  • 1. α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship.
    Chen P; Wang S; Cao C; Ye W; Wang M; Zhou C; Chen W; Zhang X; Zhang K; Zhou W
    Bioorg Chem; 2021 Nov; 116():105295. PubMed ID: 34455300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation.
    Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W
    Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
    Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
    J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors.
    Dong J; Wang Z; Cui J; Meng Q; Li S
    Eur J Med Chem; 2020 Feb; 187():111938. PubMed ID: 31830634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors.
    Dong J; Huang G; Cui Q; Meng Q; Li S; Cui J
    Eur J Med Chem; 2021 Jan; 209():112895. PubMed ID: 33069055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of selective CYP1B1 inhibitor via dearomatization of α-naphthoflavone.
    Kubo M; Yamamoto K; Itoh T
    Bioorg Med Chem; 2019 Jan; 27(2):285-304. PubMed ID: 30553624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance.
    Yao X; Mao J; Zhang H; Xiao Y; Wang Y; Liu H
    Eur J Med Chem; 2024 Jun; 272():116488. PubMed ID: 38733885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
    Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
    Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study.
    Juvonen RO; Jokinen EM; Javaid A; Lehtonen M; Raunio H; Pentikäinen OT
    Chem Biol Drug Des; 2020 May; 95(5):520-533. PubMed ID: 32060993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective of structural flexibility on selective inhibition towards CYP1B1 over CYP1A1 by α-naphthoflavone analogs.
    Wang Y; Hu B; Zhang Y; Wang D; Luo Z; Wang J; Zhang F
    Phys Chem Chem Phys; 2021 Sep; 23(36):20230-20246. PubMed ID: 34474468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis of 4,6-diaryl-2-pyridones and their bioactivation in CYP1 expressing breast cancer cells.
    Ruparelia KC; Lodhi S; Ankrett DN; Wilsher NE; Arroo RRJ; Potter GA; Beresford KJM
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1403-1406. PubMed ID: 30935796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycyrrhiza glabra extract and quercetin reverses cisplatin resistance in triple-negative MDA-MB-468 breast cancer cells via inhibition of cytochrome P450 1B1 enzyme.
    Sharma R; Gatchie L; Williams IS; Jain SK; Vishwakarma RA; Chaudhuri B; Bharate SB
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5400-5403. PubMed ID: 29150398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
    Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F
    Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new class of CYP1B1 inhibitors derived from bentranil.
    Yi L; Huang X; Yang M; Cai J; Jia J; Peng Z; Zhao Z; Yang F; Qiu D
    Bioorg Med Chem Lett; 2023 Jan; 80():129112. PubMed ID: 36565966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis and Binding Affinity Evaluation of Cytochrome P450 1B1 Targeted Chelators.
    Chen D; Fan Q; Xu T; Dong J; Cui J; Wang Z; Wang J; Meng Q; Li S
    Anticancer Agents Med Chem; 2022; 22(2):261-269. PubMed ID: 33820523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance.
    Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of cytochrome P450 (CYP) 1B1.
    Dutour R; Poirier D
    Eur J Med Chem; 2017 Jul; 135():296-306. PubMed ID: 28458135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.
    Chang I; Mitsui Y; Kim SK; Sun JS; Jeon HS; Kang JY; Kang NJ; Fukuhara S; Gill A; Shahryari V; Tabatabai ZL; Greene KL; Dahiya R; Shin DM; Tanaka Y
    Oncotarget; 2017 Jun; 8(24):39087-39100. PubMed ID: 28388569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Synthesis of Chalcones as Anticancer Prodrugs and their Bioactivation in CYP1 Expressing Breast Cancer Cells.
    Ruparelia KC; Zeka K; Ijaz T; Ankrett DN; Wilsher NE; Butler PC; Tan HL; Lodhi S; Bhambra AS; Potter GA; Arroo RRJ; Beresford KJM
    Med Chem; 2018; 14(4):322-332. PubMed ID: 29332599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines.
    Horley NJ; Beresford KJ; Chawla T; McCann GJ; Ruparelia KC; Gatchie L; Sonawane VR; Williams IS; Tan HL; Joshi P; Bharate SS; Kumar V; Bharate SB; Chaudhuri B
    Eur J Med Chem; 2017 Mar; 129():159-174. PubMed ID: 28222316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.